| Literature DB >> 35740707 |
Wan-Hsuan Chen1, Oi-Wa Chan2, Jainn-Jim Lin2,3, Ming-Chou Chiang4, Shao-Hsuan Hsia2, Huei-Shyong Wang3, En-Pei Lee2, Yi-Shan Wang3, Cheng-Yen Kuo3, Kuang-Lin Lin3.
Abstract
BACKGROUND: Neonatal encephalopathy is caused by a wide variety of acute brain insults in newborns and presents with a spectrum of neurologic dysfunction, such as consciousness disturbance, seizures, and coma. The increased excitability in the neonatal brain appears to be highly susceptible to seizures after a variety of insults, and seizures may be the first clinical sign of a serious neurologic disorder. Subtle seizures are common in the neonatal period, and abnormal clinical paroxysmal events may raise the suspicion of neonatal seizures. Continuous video electroencephalographic (EEG) monitoring is the gold standard for the diagnosis of neonatal seizures. The aim of this study was to identify the prevalence of electrographic seizures and the impact of monitoring in neonates with a high risk of encephalopathy.Entities:
Keywords: a high risk of encephalopathy; continuous; electroencephalographic monitoring; electrographic seizure; neonate
Year: 2022 PMID: 35740707 PMCID: PMC9221774 DOI: 10.3390/children9060770
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Scheme 1Screenshots of EEG changes in a certain behavior from Supplementary Video S1. The EEG seizure was started from the left frontal area (Fp1) with subtle lip smacking and body movement (A,B), followed by EEG evolution without clinical movements (C,D). The duration was 1 min.
Figure 1Study flow chart. During the 4-year study period, 71 neonates with a high risk of encephalopathy were enrolled, including 42 (59.2%) who were monitored for acute neonatal encephalopathy (ANE) and 29 (40.8%) who were monitored for other high-risk encephalopathy conditions (OHRs). Electrographic seizures were captured in 25 (35.2%) of the 71 neonates, including 17 (40.5%) of the 42 neonates in the ANE group and 8 (27.6%) of the 29 of neonates in the OHRs group.
Characteristics of the 71 neonates with a high risk of encephalopathy.
| Characteristic | ANE | OHRs | |
|---|---|---|---|
|
| 0.026 * | ||
| Male | 22 (52.4%) | 23 (79.3%) | |
| Female | 20 (47.6%) | 6 (20.7%) | |
|
| |||
|
| 0.020 * | ||
| Preterm (<34 weeks) | 5 (11.9%) | 9 (31.1%) | |
| Late Preterm (34–37 weeks) | 7 (16.7%) | 7 (24.1%) | |
| Term (>37 weeks) | 30 (73.7%) | 13 (44.8%) | |
|
| 0.082 | ||
| <1500 | 4 (9.5%) | 8 (27.6%) | |
| 1500–2500 | 8 (19.0%) | 7 (24.1%) | |
| >2500 | 30 (71.5%) | 14 (48.3%) | |
|
| |||
| 1 min | 4 (1–6) | 7 (5–8) | <0.001 * |
| 5 min | 5 (4–8) | 9 (7–9) | <0.001 * |
| Median (range) | 39 (37–41) | 38 (34–40) | 0.119 |
| Preterm (<34 weeks) | 2 (4.8%) | 7 (24.1%) | 0.020 * |
| Late Preterm (34–37 weeks) | 7 (16.7%) | 1 (3.4%) | |
| Term (>37 weeks) | 33 (78.6%) | 21 (72.5%) | |
| - | |||
| Subtle (eye blinking, mouthing, and fisting) | 1 (2.4%) | 2 (6.9%) | |
| Clonic | 4 (9.5%) | 2 (6.9%) | |
| Tonic | 1 (2.4%) | 0 | |
| Myoclonic | 1 (2.4%) | 0 | |
| Non-motor (autonomic symptoms) | 1 (2.4%) | 0 | |
|
| |||
| Number | 35 (83.3%) | 16 (55.2%) | 0.015 * |
|
| |||
| Median (range) | 71.6 (64.9~78.4) | 18.9 (16.6~23.7) | <0.001 * |
|
| |||
| Background | 0.033* | ||
| Normal/mild abnormalities | 9 (22.5%) | 17 (54.8%) | |
| Moderate abnormalities | 15 (37.5%) | 9 (29 %) | |
| Major abnormalities: | 13 (32.5%) | 4 (12.9%) | |
| Inactive EEG | 3 (7.5%) | 1 (3.2%) | |
|
| 17 (40.5%) | 8 (27.6%) | 0.013 * |
|
| 10 (2~54.5) | 5.5 (1~11.25) | 0.051 * |
|
| 24/38 (63.2%) | 10/27 (37.0%) | 0.710 |
|
| 0.178 | ||
| Seizure-free without the use of AEDs | 20 (54.1%) | 20 (76.9%) | |
| Favorable outcome | 11 (29.7%) | 4 (15.4%) | |
| Intractable epilepsy | 6 (16.2%) | 2 (7.7%) | |
EEG: electroencephalography; ANE: acute neonatal encephalopathy; OHRs: other high-risk encephalopathy conditions; AEDs: antiepileptic drugs. ++ 6 neonates died during the hospitalization, including 4 in the ANE group and 2 in the OHRs group. +++ 2 neonates died during the 1-year follow-up period, including 1 in the ANE group and 1 in the OHRs group. * p < 0.05: statistically significant.
Scheme 2Electrographic seizures between the ANE and OHRs groups. Electrographic seizures were captured in 25 of the 71 (35.2%) neonates, including five (20%) with electroclinical seizures, 11 (44%) with electrographic-only seizures, and nine (36%) with both electroclinical and electrographic-only seizures. Electrographic seizures were most commonly found in the ANE group (17, 40.5%) than in the OHRs group (8, 27.6%) (p = 0.013). ANE: acute neonatal encephalopathy; OHRs: other high-risk encephalopathy conditions; Error bars: 95% confidence interval (CI). NS: no statistic significant; * p < 0.05: statistically significant.
Neonates with a high risk of encephalopathy (n = 71) who were monitored with continuous video EEG for electrographic seizures by indication.
| Indication for Monitoring | Electrographic Seizure(s) | Subgroups of Electrographic Seizure(s) ( | ||
|---|---|---|---|---|
| Electroclinical Seizure(s) | EEG-Only | Both Electroclinical and EEG-Only Seizure(s) | ||
|
| ||||
| Perinatal asphyxia | 17/37 (45.9%) | 3/17 (4.2%) | 8/17 (47.1%) | 6/17 (35.3%) |
| Following cardiopulmonary resuscitation | 0/5 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
|
| ||||
| Genetic/IEM/metabolic | 3/12 (25%) | 0 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Prematurity with additional risk factors | 4/6 (66.7%) | 2/4 (50%) | 2/4 (50%) | 0 (0%) |
| CNS infection | 0/5 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Perinatal stroke | 0/3 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Others+ | 1/3 (33.3%) | 0 (0%) | 0 (0%) | 1/1 (100%) |
|
|
|
|
|
|
EEG: electroencephalography; EEG-only: electrographic-only; CNS: central nervous system; IEM: inborn error of metabolism. Others+: including congenital malformation and cardiac or pulmonary risk factors (Tetralogy of Fallot, extra-corporeal membrane oxygenation).
Figure 2Impact of continuous video-EEG monitoring on clinical management. Fifty-one (71.8%) neonates had received an AED during the continuous video-EEG monitoring. Finally, continuous video-EEG monitoring led to a change in AED treatment in 39.4% of the neonates (28 of 71), including initiating AEDs (2, 2.8%), AED escalation (11, 15.5%), and AED discontinuation (15, 21.1%). Six neonates died during hospitalization, and 2 neonates died during the 1-year follow-up period. In terms of seizure outcome after 1-year follow-up in 63 neonates, 40 were seizure-free without the use of AEDs, 15 had a favorable outcome and 8 had intractable epilepsy. (AED: anti-epileptic drug).